Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis

Brian Chan, Karli Kondo, Michele Freeman, Chelsea Ayers, Jessica Montgomery, Devan Kansagara

Research output: Contribution to journalReview article

Abstract

Background: Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder. Methods: We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS′). Results: Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75). Discussion: Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. SR Registration: Prospero CRD42018085667.

Original languageEnglish (US)
JournalJournal of general internal medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cocaine
Meta-Analysis
Randomized Controlled Trials
Drug Therapy
Bupropion
Antipsychotic Agents
Information Storage and Retrieval
Drug Combinations
Secondary Prevention
MEDLINE
Pharmaceutical Preparations
Antidepressive Agents
Libraries
Outcome Assessment (Health Care)
Clinical Trials
Pharmacology
Recurrence
Therapeutics

Keywords

  • cocaine
  • pharmacotherapy
  • substance use
  • systematic review

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis. / Chan, Brian; Kondo, Karli; Freeman, Michele; Ayers, Chelsea; Montgomery, Jessica; Kansagara, Devan.

In: Journal of general internal medicine, 01.01.2019.

Research output: Contribution to journalReview article

Chan, Brian ; Kondo, Karli ; Freeman, Michele ; Ayers, Chelsea ; Montgomery, Jessica ; Kansagara, Devan. / Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis. In: Journal of general internal medicine. 2019.
@article{0bd8bdb5081b4160b94056180c1125d7,
title = "Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis",
abstract = "Background: Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder. Methods: We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS′). Results: Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95{\%} CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95{\%} CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95{\%} CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95{\%} CI 1.03 to 1.75). Discussion: Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. SR Registration: Prospero CRD42018085667.",
keywords = "cocaine, pharmacotherapy, substance use, systematic review",
author = "Brian Chan and Karli Kondo and Michele Freeman and Chelsea Ayers and Jessica Montgomery and Devan Kansagara",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11606-019-05074-8",
language = "English (US)",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",

}

TY - JOUR

T1 - Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis

AU - Chan, Brian

AU - Kondo, Karli

AU - Freeman, Michele

AU - Ayers, Chelsea

AU - Montgomery, Jessica

AU - Kansagara, Devan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder. Methods: We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS′). Results: Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75). Discussion: Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. SR Registration: Prospero CRD42018085667.

AB - Background: Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder. Methods: We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS′). Results: Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75). Discussion: Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. SR Registration: Prospero CRD42018085667.

KW - cocaine

KW - pharmacotherapy

KW - substance use

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=85067305698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067305698&partnerID=8YFLogxK

U2 - 10.1007/s11606-019-05074-8

DO - 10.1007/s11606-019-05074-8

M3 - Review article

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

ER -